Rally #188-1-6640
Sekisui Diagnostics #1066-40
OSOM® COVID-19 Antigen Rapid Test (40/KT)
Antigen Rapid Test, COVID-19, Mid-Turbinate Swab, Lateral Flow Chromatographic Immunoassay, EUA Authorized, Rx Only
Sekisui Diagnostics 2025 Promotion: Respiratory
Test for multiple respiratory infections with trusted OSOM® rapid tests!
Buy 6 kits for the price of 5 — mix and match from eligible OSOM® respiratory test kits.
Offer Valid Through September 30, 2025
See Details Below
- Detects active COVID-19 infection quickly using a reliable chromatographic immunoassay.
- Designed for use with mid-turbinate nasal swabs to enhance patient comfort and sampling accuracy.
- Delivers clear and easy-to-interpret results in just 15 minutes without the need for instruments.
- Includes all components required to run the test, supporting fast setup and efficient workflow.
- Features strong positive and negative agreement to support confident diagnostic decisions.
This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The OSOM COVID-19 Antigen Rapid Test is intended for use by healthcare professionals or operators who are proficient in performing tests in point of care settings.
Important Notes
- Restricted Product: Rx Only - Current Valid Medical License Required.
- Product is non-returnable; please make sure it is the right product before ordering.
- Testing must be performed within 30 minutes of specimen collection.
- For In Vitro Diagnostic Use
- For Directly Collected Mid-turbinate Nasal Swab Specimens
- For Use Under Emergency Use Authorization (EUA) Only
- For more information on this product's EUA, please go to the EUA section below.
Rally # | 188-1-6640 |
Manufacturer # | 1066-40 |
Brand | OSOM® |
Manufacturer | Sekisui Diagnostics |
Country of Origin | United States |
Application | Respiratory Test Kit |
Number of Tests | 40 Tests |
Reading Type | Visual Read |
Sample Type | Direct Mid-Turbinate Nasal Swab Sample |
Specialty | Immunoassay |
Test Format | Test Device Format |
Test Kit Type | Rapid |
Test Method | Lateral Flow Chromatographic Immunassay |
Test Name | Covid-19 Antigen |
Time to Results | 15 Minute Results |
UNSPSC Code | 41116144 |
Storage Temperature | 15-30 °C / 59-86 °F |
Positive Percent Agreement* | 95.1% |
Negative Percent Agreement* | 97.0% |
*Compared to RT-PCR. See IFU.
Configurations
Product ID | Description | Quantity |
1066-40 | OSOM® COVID-19 Antigen Rapid Test | 40 Tests Per Kit |
1068 | OSOM® COVID-19 Antigen Control Kit | 5 x SARS-CoV-2 Positive Control Swabs 5 x SARS-CoV2 Negative Control Swabs |
Materials Provided in Each Test Kit
Material | Description | Quantity |
OSOM COVID-19 Antigen Test Devices | Test devices containing LFI test strip in a plastic housing | 40 |
OSOM Antigen Buffer Tubes | Nasal swab specimen collection & dispensing tube containing OSOM Antigen Buffer | 2 x 20 |
Sterile, Nasal Swabs | Mid-Turbinate Nasal Swab | 40 |
Instructions For Use (IFU) | 1 | |
Quick Reference Guide | For Direct Nasal Swab Samples | 1 |
Documentation Links
Promotional Information
Sekisui Diagnostics 2025 Promotion: Respiratory
Test for multiple respiratory infections with trusted OSOM® rapid tests!Buy 6 kits for the price of 5 — mix and match from eligible OSOM® respiratory test kits.
Offer Valid Through September 30, 2025 OnlyEligible Products:
- OSOM® COVID-19 Antigen Rapid Test (cat. no. 1066-40)
- OSOM® Ultra Plus Flu A&B Test (cat. no. 1032)
- OSOM® RSV Test (cat. no. 1091)
- OSOM® Flu SARS-CoV-2 Combo Test (cat. no. 1080)
- Purchase any five kits (any combination) on a single invoice to qualify.
- To receive your kits, submit redemptions online at osompromos.com.
- All redemptions must be submitted by the deadline listed on the official promotion flyer (link below).
- Proof of purchase required.
- Customers will receive proof of purchase from Rally Inc. once their order has been processed.
- Sekisui Diagnostics is solely responsible for all aspects of the promotion, including eligibility determination, redemption processing, and fulfillment.
- Rally Inc. is not liable for the administration of the promotion, delays in fulfillment, or any changes to the offer.
- Rally Inc. does not assume responsibility for any modifications to promotion terms, product eligibility, or redemption requirements made by Sekisui Diagnostics.
- Customers are responsible for reviewing and following all redemption instructions provided by Sekisui Diagnostics.
- All promotional terms, conditions, and availability are determined by Sekisui Diagnostics and are subject to change without notice.
Reimbursement Information
This product may be eligible for reimbursement depending on current laws, policies, and individual circumstances. Please note that Rally Inc. does not handle, manage or process any reimbursements. All reimbursement matters are handled directly between you and the product manufacturer. To determine your eligibility and request reimbursement, please follow the manufacturer's reimbursement guidelines and instructions.
You can find more information on reimbursement details for this product below:
Link: https://www.codemap.com/sekisui/userhome.cfm.
Disclaimer:
Rally Inc. assumes no responsibility for the accuracy, completeness, or timeliness of the reimbursement information provided by the product manufacturer. Reimbursement policies are subject to change, and customers are encouraged to contact the product manufacturer directly for the most current information.
Manufacturer contact information for current product:
Sekisui Diagnostics:
https://sekisuidiagnostics.com/contact-us/.
EUA - Emergency Use Authorization
This test has not been FDA cleared or approved. It is authorized by FDA under an EUA for use by authorized laboratories. It has been authorized only for the detection of SARS-CoV-2 antigen, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.For more information on the product's EUA, please see the product's package insert on the Education & Documents Section.